Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers seek genetic clues to identify addicts and patients who will benefit from treatment

29.07.2002


Toxicology experts have long known that individuals can exhibit a wide range of physiological responses when exposed to identical doses of opiate- or morphine-based drugs. This drug class includes illicit drugs such as heroin, as well as regulated drugs like methadone and oxycontin, which have legitimate uses in addiction treatment and pain management. Unfortunately, an individual’s response to these drugs can be gauged only after the drug has been administered, leaving care givers to make an educated guess as to how much drug to give in order to achieve the intended effect.



Now, a team of researchers suggests that “pharmacogenomic” testing may be a way to help drug-treatment centers select appropriate treatment regimens for their opiate-addicted patients, and it may also provide valuable information in the care of patients who require substantial levels of pharmacological pain management.

Background


The most common treatment for heroin addiction is methadone, used because of its ability to produce psychic and physical dependence, but with significantly milder withdrawal symptoms than heroin. Previously published studies have documented methadone toxicity and noted a higher risk in the initial treatment periods for some patients.

Scientists know that the toxicity of this synthetic narcotic is affected in part by a patient’s metabolism of the drug. Methadone is metabolized by enzymes CYP1A2, CYP2D6 and CYP 3A4. CYP 2D6 is unique in that it is also a key to the metabolism of other opioids, such as codeine and tricyclic antidepressants.

A recent peer-reviewed article—“Pharmacogenomics as Molecular Autopsy for Forensic Pathology/Toxicology: Does Genotyping CYP 296 Serve as an Adjunct for Certifying Methadone Toxicity?”—looks at the possibility of using laboratory-based testing to identify genetic polymorphisms that affect the way an individual metabolizes the opioid class of drugs. The authors are Steven H. Wong, PhD; Michael A. Wagner, PhD; Jeffrey M. Jentzen, MD; Chuck Shur; Jeanette Bjerke; Susan B. Gock; and Chung-Che Jeffrey Chang, MD, PhD, all with the Department of Pathology, Medical College of Wisconsin in Milwaukee. Drs. Wong, Wagner, Jentzen, and Ms. Gock are also affiliated with the Milwaukee County Medical Examiner’s Office.

Results

In their current study, the authors conclude that complex medical and prescription histories often make it difficult to conclude that a CYP 2D6-encoded enzyme deficiency is the sole cause of a methadone mortality, or even contributed to death. They also note that the results generated by their genotyping investigations would not have prompted a change in the medical examiners ruling on cause of death. Nevertheless, the authors say that their study is an important first step in the effort to link genotyping with individuals’ responses to treatment therapies such as methadone, and that establishing this relationship will have a great impact in drug-abuse treatment and pain management.


This study is being presented at the 54th Annual Meeting of the American Association for Clinical Chemistry (AACC) in Orlando, Fla., July 29-August 1, 2002. AACC (http://www.aacc.org/) is the scientific organization for clinical laboratory professionals, physicians, and research scientists. Their primary commitment is the understanding of laboratory testing to identify, monitor and treat human disease. More than 14,000 attendees are expected for the meeting, which is being held at the Orange County Convention Center, Orlando, Fla., July 28-August 1, 2002.

Donna J. Krupa | EurekAlert!
Further information:
http://www.aacc.org

More articles from Health and Medicine:

nachricht Biofilm discovery suggests new way to prevent dangerous infections
23.05.2017 | University of Texas at Austin

nachricht Another reason to exercise: Burning bone fat -- a key to better bone health
19.05.2017 | University of North Carolina Health Care

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?

Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.

Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

How herpesviruses win the footrace against the immune system

26.05.2017 | Life Sciences

Water forms 'spine of hydration' around DNA, group finds

26.05.2017 | Life Sciences

First Juno science results supported by University of Leicester's Jupiter 'forecast'

26.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>